About 31 results found for searched term "STAT6-IN-1" (0.296 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49689 | STAT6-IN-1 | STAT |
| STAT6-IN-1 is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM). | ||
| M1711 | Febuxostat (TEI-6720) | Xanthine Oxidase |
| TEI-6720; Uloric; TMX-67 | ||
| Febuxostat (TEI-6720) is a non-purine selective xanthine oxidase inhibitor with IC50 of 114 -210 nM. | ||
| M1775 | Tubastatin A hydrochloride | HDAC |
| Tubastatin A HCl; TSA HCl | ||
| Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 values of 15 nM. | ||
| M1780 | Vorinostat | HDAC |
| SAHA; Zolinza; MK-0683; Suberoylanilide hydroxamic acid | ||
| Vorinostat (SAHA, Zolinza, MK-0683) is a selective and potent histone deacetylase (HDAC) inhibitor with the IC50 value of 10 nM for HDAC-1. | ||
| M2147 | Ilomastat | MMP |
| GM6001; Galardin | ||
| Ilomastat (GM6001; Galardin) is a broad spectrum matrix metalloprotease (MMP) inhibitor with Ki values of 0.4 nM, 0.5 nM, 27 nM, 3.7 nM, 0.1 nM, 0.2 nM, 3.6 nM, 13.4 nM and 0.36 nM for MMPs -1, -2, -3, -7, -8, -9, -12, -14 and -26, respectively. Ilomastat (GM6001; Galardin) reduces infarct volume following middle cerebral artery occlusion in an ischemic mouse model. | ||
| M2829 | Marimastat | MMP |
| BB2516; TA2516 | ||
| Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. | ||
| M2878 | Nexturastat A | HDAC |
| Nexturastat A is a potent and selective HDAC6 inhibitor with IC50 of 5 nM, >190-fold selectivity over other HDACs. | ||
| M3095 | Tubastatin A | HDAC |
| Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). | ||
| M5233 | Osilodrostat | Mineralocorticoid Receptor |
| LCI699 | ||
| Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. | ||
| M5259 | Citarinostat | HDAC |
| ACY-241 | ||
| Citarinostat (ACY-241) is an orally available selective HDAC6 inhibitor with IC50 of 2.6 nM and 46 nM for HDAC6 and HDAC3, respectively. It has 13 to 18-fold selectivity towards HDAC6 in comparison to HDAC1-3. | ||
| M5402 | Alvelestat (AZD9668) | Elastase |
| AZD9668 | ||
| Alvelestat (AZD9668) is an oral, highly selective inhibitor of neutrophil elastase (NE) with IC50 and Ki of 12 nM and 9.4 nM, at least 600-fold more selective over other serine proteases. | ||
| M6136 | Epacadostat | IDO |
| INCB024360 | ||
| Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM and displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). | ||
| M6287 | GLPG1690 | PDE |
| Ziritaxestat | ||
| Ziritaxestat (GLPG1690) is a first-in-class autotaxin (ATX) inhibitor, with IC50 of 131 nM and Ki of 15 nM. | ||
| M7539 | AS1517499 | STAT |
| AS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM. | ||
| M9911 | Lixumistat | Mitochondrial Related |
| IM156; HL156A | ||
| Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat (IM156) is a metformin derivative, which increases AMPK phosphorylation. | ||
| M10370 | Larazotide acetate | Others |
| AT-1001 | ||
| Larazotide acetate also known as AT-1001, is a tight junction regulator and reverses leaky junctions to their normally closed state. Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. | ||
| M10778 | Aldumastat | Others |
| GLPG1972 | ||
| Aldumastat (GLPG1972; S201086) is a potent, selective, orally active ADAMTS-5 (IC50=19 nM) inhibitor, whose selectivity is ADAMTS-4 (IC50=8 times 156 nM). Aldumastat has antimetabolic activity for osteoarthritis research. | ||
| M10943 | Atabecestat | BACE |
| JNJ-54861911 | ||
| Atabecestat (JNJ-54861911) is a potent brain-osmotic and has oral activity β-position amyloid precursor protein lyase 1 (BACE1 inhibitors that strongly reduce the expression of Aβ protein in cerebrospinal fluid. Atabecestat (JNJ-54861911) is tolerant and has sustained pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Atabecestat (JNJ-54861911) has the potential to be used in the study of Alzheimer's disease. | ||
| M10968 | STAT5-IN-2 | STAT |
| STAT5-IN-2 is an inhibitor of STAT5 in K562 and KU812 cells EC50 9 μM and 5 μM respectively, the name in Document 1 is 17f. STAT5-IN-2 has highly effective antileukemia activity. | ||
| M11321 | Angiopeptin TFA | Somatostatin Receptor |
| Angiopeptin TFA, a cyclic octapeptide analog of somatostatin, is an SST2 / SST5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA inhibits growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential to be used in the study of coronary atherosclerosis. | ||
| M11427 | RM-018 | Ras |
| INDEX NAME NOT YET ASSIGNED | ||
| RM-018 is an inhibitor of the active state of KRASG12C. Rm-018 retains the ability to bind and inhibit KRASG12C/Y96D. Rm-018 combines with GTP-bound to activate the [" RAS(ON) "] state of KRASG12C. | ||
| M13371 | Onametostat (JNJ-64619178) | PRMTs |
| Onametostat (JNJ-64619178) is a highly selective, orally active, pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (PRMT5-MEP-50, IC50=0.14 nM).Onametostat does not covalently bind to PRMT5, but has a long interaction time. It has good pharmacokinetic properties as well as safety profile. | ||
| M14069 | Numidargistat dihydrochloride | Others |
| CB-1158 dihydrochloride; INCB01158 dihydrochloride | ||
| Numidargistat (CB-1158) dihydrochloride is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent. | ||
| M14297 | Fidarestat | Others |
| SNK 860 | ||
| Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease. | ||
| M15047 | Recombinant Mouse OSM (HEK 293) | Cytokines and Growth Factors |
| OncoM; oncostatin M | ||
| Protein Construction：OSM (Ala24-Arg206) Oncostatin M (OSM) is a multifunctional cytokine belonging to the interleukin-6 (IL-6) subfamily, which also includes IL-11, leukemia suppressor (LIF), ciliary nerve promoter, cardiac trophic factor-1 and novel nerve promoter factor-1. Protein structure: OSM (ALA24-ARG206), Accession # : P53347. | ||
| M15080 | Recombinant Human OSM (E.coli, N-6His) | Cytokines and Growth Factors |
| Oncostatin-M; OSM | ||
| Recombinant human Oncostatin M is produced by escherichia coli expression system, and the target gene encoding AlA26-ARG221 was expressed at the N-terminal with 6His marker. Measured by the dose-dependent stimulation of TF-1 cells. The ED50 for this effect is 0.2-1 ng/ml. | ||
| M19040 | Bruceantinol | STAT |
| Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC50=2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc. | ||
| M20389 | Quisinostat (JNJ-26481585) 2HCl | HDAC |
| Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11 greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2. | ||
| M20718 | Tubastatin A TFA | HDAC |
| Tubastatin A trifluoroacetate salt | ||
| Tubastatin A TFA (Tubastatin A trifluoroacetate salt) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis. | ||
| M20724 | RCM-1 | IL Receptor/Related |
| Robert Costa Memorial drug-1 | ||
| RCM-1 is a nontoxic inhibitor of Forkhead box M1 (FOXM1) that suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. RCM-1 decreases carcinogenesis and nuclear β-catenin. | ||
| M21159 | SD-36 | PROTAC |
| SD-36 is a potent STAT3 PROTAC degradation agent (Kd=~50 nM) with a high selectivity compared to other STAT members. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
